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Abstract 
Rheumatoid meningitis is a rare and very serious extra-articular manifestation of rheumatoid arthritis. We 
present a case of a 72-year-old female with no history of arthritis who developed stroke-like symptoms, 
seizures, psychosis and compulsive behavior. Serial brain magnetic resonance images (MRI) over four 
months demonstrated progressive interhemispheric meningeal thickening. She had mild lymphocytic 
pleocytosis on the cerebrospinal fluid analysis and serum anti-cyclic citrullinated peptide antibodies 
resulted positive in high titers. She underwent a brain biopsy showing necrotizing granulomas consistent 
with rheumatoid meningitis. Her symptoms resolved with treatment with glucocorticoids and 
cyclophosphamide. She has not been diagnosed with rheumatoid arthritis even after 1 year of follow up. 
Clinicians should be aware of the possibility of rheumatoid meningitis without rheumatoid arthritis and 
keep it on the differential for patients with aseptic meningitis and otherwise negative work up. 
Introduction 
Rheumatoid meningitis is a rare, but very serious extra-articular manifestation of rheumatoid arthritis 
(R.A)1. The prevalence is unknown, as it has only been described in case reports. Since 1954, around fifty-
four histopathologically proven cases of rheumatoid meningitis have been published, most of them in 
patients with a longstanding history of seropositive R.A. In only five reported cases, the diagnosis of 
rheumatoid meningitis preceded the diagnosis of R.A within the first 3 months of initial presentation or 
were diagnosed simultaneously 2-21. Here, we present the first case of biopsy proven rheumatoid 
meningitis in a patient without any prior history or new development of clinical arthritis after one year of 
follow up, and we highlight the value of testing for rheumatoid factor (R.F) and anti-cyclic citrullinated 
peptide (CCP) antibodies in aseptic meningitis of unclear etiology, even in the absence of arthritis.  
Case report 
A 72-year-old African American female with a history of hypertension and peripheral vascular disease 
developed sudden onset left sided weakness and dysphasia in October 2017. Based on clinical history and 
abnormal MR imaging, she was diagnosed with a stroke at an outside institution and placed on antiplatelet 
therapy. During the following six months, she had several hospital admissions due to changes in mental 
status and seizure episodes. She also developed vivid hallucinations (visual and auditory), paranoid 
delusions, insomnia, and compulsive behavior. She was evaluated by Neurology and Psychiatry and was 
placed on different combinations of anti-epileptic drugs (divalproex, levetiracetam, lacosamide, 
gabapentin, clonazepam, lorazepam) and quetiapine for delirium without noticeable improvement, thus 
prompting transfer to a tertiary care center for evaluation and treatment. Her 12-point review of systems 
was otherwise negative. Her physical exam was remarkable for cachexia, scarring alopecia, and minimal 
hyperextension of the interphalangeal and proximal interphalangeal joints. Her neurologic exam 
demonstrated intact alertness, orientation, explicit memory, and language, though notable for 
inattentiveness, poor concentration, emotional lability, paranoid delusions, and response to internal 
stimuli. She had mild weakness of her left lower extremity. Review of the patient’s previous MR brain 
images and repeated brain MRI obtained at our institution demonstrated changes not consistent with 
ischemia but rather progressive interhemispheric meningeal disease. See Fig 1. MRA and MRV of the head 
and neck were normal. The patient underwent a lumbar puncture and the cerebrospinal fluid (CSF) 
analysis was remarkable for mild lymphocytic pleocytosis [12 white blood cells (normal 0-5/uL), 94% 
lymphocytes, 5% monocytes/macrophages, 1% neutrophils, 6 red blood cells (normal ≤ 0/uL), protein 25 
mg/dl (normal 15-45 mg/dl), glucose 58 mg/dl (normal 40-70 mg/dl), serum glucose 88 mg/dl]. Extensive 
infectious and neoplastic work up was negative, including, but not limited to syphilis, cryptococcus, HIV, 
meningitis/encephalitis panel, CJ prion testing, aerobic/anaerobic, fungal and acid-fast bacilli (AFB) 
cultures of blood and CSF; cytology and flow cytometry of the CSF. Her interferon gamma release assay 
(QuantiFERON) testing was initially borderline positive, but repeat testing was negative. Autoimmune 
work up revealed mildly elevated inflammatory markers (Erythrocyte sedimentation rate 39 mm/hr and 
C-reactive protein 0.9 mg/dl) and high levels of CCP IgG (197.5 units, ref 0-19). Serum antinuclear 
antibody, rheumatoid factor and anti-neutrophil cytoplasmic antibodies were negative. Hand x-rays were 
not obtained due to patient’s refusal. Bilateral foot x-rays were normal. The patient underwent a right 
frontal lobe biopsy, which showed necrotizing granulomas in the leptomeninges and dura mater 
consistent with rheumatoid meningitis. See Fig 2. Special stains for bacteria, mycobacteria and fungi were 
negative. An IgG4 immunohistochemistry stain was also non-diagnostic. The patient was treated with IV 
methylprednisolone 1 g daily for 5 days and cyclophosphamide 500 mg/m2 for four monthly doses with 
resolution of meningeal enhancement on follow up brain MRI (see Fig 3) and resolution of the patient’s 
hallucinations and emotional lability. The initial borderline QuantiFERON test was interpreted as a false 
positive result given the negative AFB stains and cultures, absence of risk factors in the patient’s history 
and, in retrospect analysis, her clinical improvement with immunosuppressive therapy.  
 
 Figure 1. MRI Brain with and without contrast. Coronal view T1 sequence showing diffuse post-contrast leptomeningeal 
enhancement. No parenchymal disease. 
 
 Figure 2. Biopsy of the right frontal lobe cortex and meninges (40x) with predominantly leptomeningeal inflammatory process 
with extensive necrosis (circle) and multinucleated giant cells (inset). Special stains for bacteria (Brown-Brenn), fungi (Grocott), 
and mycobacteria (Kinyoun auramine-rhodamine) are negative for organisms. 
  
Figure 3. Post-Cyclophosphamide MRI Brain with and without contrast. Coronal view T1 sequence showing resolution of 
previous leptomeningeal enhancement 
Discussion 
Rheumatoid arthritis can cause pachymeningitis, leptomeningitis or a combination of both. The 
inflammation can be localized or diffuse and involve the meninges surrounding the brain or the spinal 
cord. It usually causes asymmetric meningeal involvement. Rheumatoid meningitis has been seen almost 
exclusively in patients with a longstanding history of seropositive rheumatoid arthritis, even if their 
disease has been in remission. 1, 3  
The clinical manifestations of rheumatoid meningitis are diverse, including: headaches, meningismus, 
stroke like symptoms, cranial neuropathies, seizures, impairment of vigilance and consciousness, 
hydrocephalus, sinus thrombosis, dementia, parkinsonism and behavioral modifications. 1, 8, 21 
Rheumatoid meningitis is a diagnosis of exclusion and requires a combination of lumbar puncture, brain 
MRI and brain biopsy to establish the diagnosis. The CSF analysis can be normal or show modest 
lymphocytic pleocytosis, mildly elevated protein and/or slightly decreased glucose levels. R.F and 
interleukin-6 levels have also been found to be elevated in the CSF of patients with rheumatoid meningitis. 
Brain MRI findings include meningeal thickening and contrast enhancement on fluid-attenuation inversion 
recovery images (FLAIR) or diffusion-weighted sequences. Biopsy of the lesions identified by MRI reveal a 
characteristic, but nonspecific, mononuclear cell infiltration of the meninges with T and B cell lymphocytes 
and abundant plasma cells. Rheumatoid nodules within the meninges are specific for rheumatoid 
meningitis but are not always seen. They are composed of focal areas of necrosis surrounded by palisaded 
epithelioid giant cells. Granulomatous inflammation and vasculitis can be present. 1, 3, 4, 6, 8 
It is important to exclude other inflammatory or infiltrative diseases, such as infections (HSV, VZV, 
enteroviruses, tuberculous meningitis, atypical mycobacteria, neuroborreliosis, fungal infections, 
meningovascular syphilis, etc.), lymphoma, meningeal metastasis, drug induced (non-steroidal anti-
inflammatory drugs, tumor necrosis factor alpha inhibitors), neurosarcoidosis, antineutrophil cytoplasmic 
autoantibody-associated vasculitis (mainly granulomatosis with polyangiitis), immunoglobulin G4-related 
disease, giant cell arteritis and neuro-Behcet’s 1,3-5, 17, 21 
A thorough investigation to rule out infectious and malignant etiologies is necessary before starting 
immunosuppressive therapy. There are no guidelines or clinical trials that have studied the optimal agent 
or treatment duration in rheumatoid meningitis patients, but there are anecdotal experiences with 
steroids (usually intravenous pulses of methylprednisolone) and steroid sparing agents, such as 
methotrexate, azathioprine, cyclosporine, cyclophosphamide and rituximab. Limited data available 
suggest that tumor necrosis factor alpha inhibitors (TNFi) are not effective. We preferred to use 
cyclophosphamide in our patient in order to improve medication adherence, central nervous system 
penetration and quicker onset of action. In terms of prognosis, in the largest case series reported by 
Bathon et al, 3 out of 19 patients died from systemic necrotizing vasculitis associated with R.A and 14 died 
of other causes (sepsis, cardiac disease). 1, 3, 5, 6, 17, 18, 23 
Our case is unique in that this is the first description of a patient with biopsy proven rheumatoid meningitis 
who has not developed symptoms or signs of arthritis after 1 year of follow up from her initial 
presentation. This emphasizes the importance of keeping rheumatoid meningitis in the differential 
diagnosis of aseptic meningitis (pachy- or lepto- meningitis), when alternative etiologies have been ruled 
out and testing for rheumatoid factor and CCP antibodies even in the absence of arthritis. We should 
contemplate the possibility that the prevalence of rheumatoid meningitis may have been underestimated 
over the years because of underdiagnosis. Our patient did have minimal hyperextension of few 
interphalangeal joints of her hands, but in the absence of radiological evaluation, this is difficult to 
interpret as a sign of early arthropathy versus a benign finding.  
Additionally, to our knowledge, this is the first reported case of rheumatoid meningitis presenting with 
psychotic features with visual and auditory hallucinations, which completely resolved after 
immunosuppressive therapy. 
As a final thought, one could argue that there are no pathognomonic histopathologic features of 
rheumatoid meningitis and that the possibility of neurosarcoidosis remains, however neurosarcoidosis 
usually causes non caseating granulomas and affects the meninges at the skull base, rather than at the 
brain convexity. 13 Furthermore, CCP antibody is highly specific for R.A (more than 90% specificity). 22 Our 
patient was worked up for possible sarcoidosis with computed tomography scan of her chest, abdomen 
and pelvis to look for lymphadenopathy and with angiotensin converting enzyme levels in the CSF, all of 
which were unremarkable.  
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